Skip to main content

Table 3 Characteristics of publications included in the meta-analysis

From: Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines

Year

Studies

Participants

Age (years)

Perfusion

studies

LGE

studies

Median GBCA dose (mmol/Kg)*

Mean GBCA dose (mmol/Kg)*

2004

22 (9.5)

697 (3.5)

56.1 ± 8.7

6 (17.6)

16 (8.1)

0.15

0.16 ± 0.06

2005

19 (8.2)

2,123 (10.7)

54.4 ± 8.4

2 (5.9)

17 (8.6)

0.2

0.19 ± 0.03

2006

26 (11.1)

4,366 (22.0)

54.9 ± 11.3

5 (14.8)

21 (10.5)

0.2

0.18 ± 0.04

2007

31 (13.3)

1,123 (5.6)

46.1 ± 16.9

3 (8.9)

28 (14.1)

0.2

0.18 ± 0.10

2008

40 (17.1)

2,264 (11.3)

55 ± 8.9

7 (20.5)

33 (16.5)

0.2

0.18 ± 0.03

2009

45 (19.3)

3,965 (19.9)

56.2 ± 10.3

5 (14.7)

40 (20.1)

0.2

0.18 ± 0.04

2010

50 (21.5)

5,396 (27.0)

55 ± 11.3

6 (17.6)

44 (22.1)

0.2

0.18 ± 0.04

Total

233 (100)

19,934 (100)

54.2 ± 11.4

34 (100)

199 (100)

0.2

0.18 ± 0.04

  1. Median, Mean and standard deviations or number and percentages as appropriate. LGE, late gadolinium enhancement.
  2. Studies that had both LGE and perfusion results were categorized as LGE. For these studies, total gadolinium dose is shown.